| 產(chǎn)品名稱 | MHY 908 |
| 產(chǎn)品貨號(hào) | Axon 2402 CAS [1393371-39-5] MF C17H14ClNO3SMW 347.82 Purity: 99% Soluble in 0.1N NaOH(aq) and DMSO Description Dual PPARα/γ agonist, and potent inhibitor of melanogenesis by inhibition of mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 more potently activated PPARα and PPARγ than fenofibrate and rosiglitazone, respectively, and?enhanced the binding and transcriptional activity of PPARα and -γ in AC2F cells. It reduced serum glucose, triglyceride, and insulin levels, however increased adiponectin levels without body weight gain. In addition, MHY 908 significantly improved hepatic steatosis by enhancing CPT-1 levels. Remarkably, MHY-908 reduced endoplasmic reticulum (ER) stress and c-Jun N-terminal kinase (JNK) activation, and subsequently reduced insulin resistance. References Certificates Categories Extra info M.H. Park et al. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice. PLoS One. 2013 Nov 14;8(11):e78815. ? M.H. Park et al. Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908). Arch Pharm Res. 2014 Dec 14. [Epub ahead of print] Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Diabetes & Metabolism PPAR Tyrosinase NR1C; EC 1.14.18.1 Dual PPARα/γ agonist, and potent inhibitor of mushroom tyrosinase Chemical name 2-(4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy)-2-methylpropanoic acid Parent CAS No. [1393371-39-5] Order Size Unit Price Stock 5 mg €95.00 In Stock |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
MHY 908Axon 2402 CAS [1393371-39-5] MF C17H14ClNO3S
DescriptionDual PPARα/γ agonist, and potent inhibitor of melanogenesis by inhibition of mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 more potently activated PPARα and PPARγ than fenofibrate and rosiglitazone, respectively, and?enhanced the binding and transcriptional activity of PPARα and -γ in AC2F cells. It reduced serum glucose, triglyceride, and insulin levels, however increased adiponectin levels without body weight gain. In addition, MHY 908 significantly improved hepatic steatosis by enhancing CPT-1 levels. Remarkably, MHY-908 reduced endoplasmic reticulum (ER) stress and c-Jun N-terminal kinase (JNK) activation, and subsequently reduced insulin resistance.
Dual PPARα/γ agonist, and potent inhibitor of mushroom tyrosinase
Chemical name2-(4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy)-2-methylpropanoic acid Parent CAS No.[1393371-39-5] |
| 產(chǎn)品資料 |
